References
- Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 2016;34:1097–103.
- Langer AL, Miao S, Mapara M, Radhakrishnan J, Maurer MS, Raza S, Mearset JG, et al. Results of phase I study of chimeric fibril-reactive monoclonal antibody 11-1f4 in patients with AL amyloidosis. Blood 2015;126:188.
- Wall JS, Richey T, Stuckey A, Donnell R, Macy S, Martin EB, Williams A, et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci USA 2011;108:E586–94.
- Wall JS, Martin EB, Richey T, Stuckey AC, Macy S, Wooliver C, Williams A, et al. Preclinical validation of the heparin-reactive peptide p5 + 14 as a molecular imaging agent for visceral amyloidosis. Molecules 2015;20:7657–82.